|
 |
|
|
|
JOB FUNCTIONS |
Laboratory Management
Corporate Management
Heads of Manufacturing
Heads of Research Projects
Heads of Product Development
IT Managers
Heads of Production
Heads of QC/QAHealth Economists
Heads of Purchasing |
|
CEO/M.D
Medical Directors
Heads of Life Science
Heads of R&D
Heads of Clinical Supply
Heads of Licensing
Heads of Procurement
Pre Clinical & Clinical Management
Heads of Formulation Development
Heads of Medical Device
Heads of Analytical Departments
Heads of Clinical Trials
Heads of Monitoring Regulatory Affairs-GMP-GLP-GCP |
| |
|
|
|
GEOGRAPHICAL CIRCULATION |
| Austria, Norway, France, Germany, Italy, Scandinavia, South Africa, Spain, Switzerland, Japan, India, United Kingdom & Ireland, USA & Canada, Central Europe (Czech Republic, Hungary, Poland, Slovakia) |
| |
|
|
|
ADVERTISING RATES |
|
WEB SITE FACILITIES |
| SIZE |
RATE
|
| FRONT COVER LOGO |
£7,450
|
| DOUBLE PAGE SPREAD |
£4,550
|
| SINGLE PAGE |
£2,750
|
| HALF PAGE |
£1,575
|
| QUARTER PAGE |
£795
|
| OPPOSITE CONTENT PAGES |
£3,750
|
| OPPOSITE EDITOR’S LETTER |
£3,750
|
| INSIDE FRONT COVER |
£4,950
|
| INSIDE BACK COVER |
£3,450
|
| OUTSIDE BACK COVER |
£5,750
|
|
|
1) Hyperlink from a relevant section of our website to client website
2) Banner and/or logo on our website (see below for banner specifications)
3) Client news page – to use for press releases during the duration of advertising.
4) Corporate profile up to 350 words
BANNER SPECIFICATIONS
GIF or JPEG (if static) or SWF (flash), 468 X 60 pix (centre or top) or 200 X 180 (right side)
All the above will be in place for as long as advertising runs |
| |
|
|
|
MECHANICAL SPECIFICATIONS REPROGRAPHIC |
|
MECHANICAL DETAILS (IN MM) |
 |
Type Size
|
Trim Size
|
Bleed Size
|
|
Double Page* |
273 x 396
|
297 x 420
|
303 x 426
|
|
One Page |
273 x 186
|
297 x 210
|
303 x 213
|
|
1/2 page (horizontal) |
135 x 186
|
148 x 210
|
151 x 213
|
|
1/2 page (vertical) |
273 x 92
|
297 x 105
|
303 x 108
|
|
1/4 page |
135 x 92
|
N/A
|
N/A
|
|
A. Electronic pictures or graphics can be supplied in the following formats:
1. Adobe Photoshop CS2 TIFF (*.tif), JPEG, PSD or EPS
2. Adobe Illustrator CS2 EPS
Electronic images/graphics must be supplied at high resolution (at least 300dpi)
Electronic images/graphics should be in CMYK colour.
Please do not send picture files embedded in Microsoft Word documents.
Please supply them as separate attachments.
B. Pictures can be supplied as good quality colour or black and white photographs
C. Client designed adverts should be supplied in one of the following ways:
1. QuarkXpress 6 (not Quark Passport). With relevant high resolution graphics and fonts also supplied.
2. Adobe Illustrator CS2. Images and graphics must be embedded. Fonts should be supplied if they are not embedded/converted to outline.
3. Adobe Acrobat PDF. Advert PDFs must be supplied optimised for high quality printing. All colours (inc. pictures) must be CMYK, no RGB or Pantone. They must include high resolution graphics (300dpi) and embedded fonts. Bleed adverts must include registration markings and bleed. We are unable to make ammendments to PDF files.
All adverts should be supplied with a colour copy of the advert. PDFs are supplied entirely at the client’s own risk and the publisher accepts no responsibility for any errors in printing.
Electronic files can be emailed to us. Larger files (above 10Mb) should be supplied to us on CD.
Electronic pictures or graphics can be supplied in the following formats:
1. Adobe Photoshop CS2 TIFF (*.tif), JPEG, PSD or EPS
2. Adobe Illustrator CS2 EPS Electronic images/graphics must be supplied at high resolution (at least 300dpi)
All adverts should be supplied with a colour copy of the advert. PDFs are supplied entirely at the client’s own risk and the publisher accepts no responsibility for any errors in printing. Electronic files can be emailed to us. Larger files (above 10Mb) should be supplied to us on CD. |
|
 |
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
News and Press Releases |
 |
Azopharma Announces Plans to Implement XcelodoseTM Technology in the Production of Early Stage Clinical Trial Materials
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today plans to implement Xcelodose technology at its formulations development facility, ApiCross Drug Delivery Technologies. Xcelodose technology is a powder micro-dosing system developed by Meridica. This technology offers a unique powder dispensing system for small-scale capsule filling and ultimately assists in conserving valuable research material as well as reducing various Preformulation activities.
More info >> |
|
|
